Metabolic disorder in chronic obstructive pulmonary disease (COPD) patients: Towards a personalized approach using marine drug derivatives

Research output: Contribution to journalReview articlepeer-review

Abstract

Metabolic disorder has been frequently observed in chronic obstructive pulmonary disease (COPD) patients. However, the exact correlation between obesity, which is a complex metabolic disorder, and COPD remains controversial. The current study summarizes a variety of drugs from marine sources that have anti-obesity effects and proposed potential mechanisms by which lung function can be modulated with the anti-obesity activity. Considering the similar mechanism, such as inflammation, shared between obesity and COPD, the study suggests that marine derivatives that act on the adipose tissues to reduce inflammation may provide beneficial therapeutic effects in COPD subjects with high body mass index (BMI).

Original languageEnglish
Article number15030081
JournalMarine Drugs
Volume15
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Keywords

  • Chronic obstructive pulmonary disease
  • Comorbidities
  • Inflammation
  • Management strategy
  • Marine compound
  • Metabolic disorder
  • Systems approaches

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint

Dive into the research topics of 'Metabolic disorder in chronic obstructive pulmonary disease (COPD) patients: Towards a personalized approach using marine drug derivatives'. Together they form a unique fingerprint.

Cite this